Arich Enterprise Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Arich Enterprise Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 304.59 million compared to TWD 254.65 million a year ago. Revenue was TWD 293.09 million compared to TWD 241.19 million a year ago. Net income was TWD 20.37 million compared to TWD 19.97 million a year ago. Basic earnings per share from continuing operations was TWD 0.27 compared to TWD 0.27 a year ago. Diluted earnings per share from continuing operations was TWD 0.27 compared to TWD 0.27 a year ago.
For the six months, sales was TWD 597.43 million compared to TWD 533.39 million a year ago. Revenue was TWD 556.85 million compared to TWD 495.67 million a year ago. Net income was TWD 37.89 million compared to TWD 32.15 million a year ago. Basic earnings per share from continuing operations was TWD 0.51 compared to TWD 0.43 a year ago. Diluted earnings per share from continuing operations was TWD 0.51 compared to TWD 0.43 a year ago.
Arich Enterprise Co., Ltd. is a Taiwan-based company principally engaged in the sales and marketing of pharmaceuticals, as well as the provision of the related logistics services. The Company is principally engaged in the sale and marketing of prescription drugs for gynaecology, obstetrics, urinary, derma and ophthalmology use; guideline drugs for hair breeding, intestines and stomach and smoking quit, as well as health consumer goods for oral health, daily consuming and beauty care, among others. The Company also provides distribution and logistics services for prescription drugs, guideline drugs, restriction drugs, cold chain drugs, clinical trial drugs and healthcare products, among others. The Company operates its business mainly within domestic market.